Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 2010. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding an increase in their personal holdings of Ordinary shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on shareholding changes rather than financial performance metrics.
Material Changes
There are no material changes to the company's financial position or operations reported in this document. The only reported activity is the re-investment of dividends paid on October 7, 2010, by specific individuals.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, or discussion of risks and contingencies. It is a compliance notification under Disclosure and Transparency Rule 3.1.4R(1)(a).
Important Facts for Investors
- Transaction Type: Increase in share interests via dividend re-investment.
- Share Price: £12.94 per Ordinary share.
- Dividend Date: October 7, 2010.
- Notified Parties: Mr A P Witty (729 shares), Mrs C M Witty (652 shares), Mr J S Heslop (507 shares), Dr D Pulman (307 shares), and Mrs C R Pulman (62 shares).
- Notification Date: October 12, 2010.